Fig. 7

CircSHKBP1 promotes GC metastasis in vivo. a and b. Bioluminescence imaging (BLI) of mice 7 weeks after tail vein injection of BGC823 LV3-NC, LV3-sh1 or LV3-sh2 cells (n = 5 per group). a Representative images. b Quantification of BLI in the lung region. c and d. BLI of mice 7 weeks after tail vein injection of BGC823 LV5-NC or LV5-circSHKBP1 cells with or without bevacizumab treatment (n = 5 per group). c Representative images. d Quantification of BLI in the lung region. e and f. Representative images of H&E staining of the mouse lung tumor burden. g and h. IHC of VEGF and HUR in lung metastatic lesions of mice. i and j. AOD of VEGF and HUR staining in lung metastatic lesions of mice. Quantitative data from three independent experiments are shown as the mean ± SD (error bars). *P < 0.05, **P < 0.01, ***P < 0.001 (Student’s t-test)